Status:
COMPLETED
The Role of ITGAM in Systemic Lupus Erythematosus
Lead Sponsor:
Northwell Health
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18-90 years
Brief Summary
Study to examine the role of ITGAM molecule in normal control subjects with known genetic variation in the ITGAM gene.
Eligibility Criteria
Inclusion
- males and females, age 18 or older, enrolled in Genotype and Phenotype Registry, in general good health
- Participants who carry the genotype of interest, based on a buccal or blood derived DNA sample
Exclusion
- History of Systemic Lupus Erythematosus, rheumatoid arthritis, or other autoimmune disease
- History of cancer or lymphoma
- Current use of aspirin, prednisone, or NSAID or any immunosuppressant
- Self reported HIV
Key Trial Info
Start Date :
December 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01230112
Start Date
December 1 2009
End Date
April 1 2012
Last Update
July 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Feinstein Institute for Medical Research
Manhasset, New York, United States, 11030